

Kidney Cancer GCOM 11 (day 1) minutes

Kidney Cancer update – committee meeting 11 (day 1) minutes

Date: 30/04/2025

Location: Virtual

Minutes: Final

Committee members present:		
Baljit Singh	Chair	Present for items 1-6
Axel Bex	Urological Surgeon	Present for items 1-6
Lisa Browning	Histopathologist	Present for items 1-4
Amarnath Challapalli	Clinical Oncologist (General)	Present for items 1-6
Amy Clifford	Clinical Oncologist (SABR)	Present for items 1-6
John Connolly	Lay Member	Present for items 1-6
David Cullen	Urology Cancer Nurse	Present for items 1-6
Stuart Evans	Oncology Pharmacist	Present for items 1-4
Geraldine Fox	Lay Member	Present for items 1-6
Fayiza Habeeb	Lead Nurse Practitioner	Present for items 1-6
David Mole	Nephrologist (co-opted member)	Present for items 1-6
Ankit Rao	Medical Oncologist	Present for items 3-6
Sandeep Singh Randhawa	General Practitioner	Present for items 2-6
Grant Stewart	Topic Adviser	Present for items 1-6
Maxine Tran	Urological Surgeon	Present for items 1-6
Tze Min Wah	Interventional Radiologist	Present for items 1-3, 5-6
James Whitworth	Clinical Geneticist (co-opted member)	Present for items 1-6
Sam Withey	Diagnostic Radiologist	Present for items 1-4

In attendance NICE:		
Marie Harrisingh	Topic Lead	Present for items 1-6
Sarah Boyce	Senior Technical Analyst	Present for items 1-6
Danielle Conroy	Project Manager	Present for items 1-6
Lindsay Claxton	Health Economics Adviser	Present for items 1-6
Olivia Crane	Senior Technical Analyst	Present for items 1-6
Benjamin Gregory	Business Analyst, Resource Impact	Present for items 2-6
Sarah Matthews	Technical Analyst	Present for items 1-6

Agnesa Mehmeti	Technical Analyst	Present for items 1-6
Manon Owen	Coordinator, Methods and Economics (Observing)	Present for items 1-6
Hannah Tebbs	Senior Health Economist	Present for items 1-6
Ellie Zachariades	Senior Guidance Content Designer	Present for items 1-2, 4-6
Yuanyuan Zhang	Senior Health Economist	Present for items 1-6

Apologies:

Janet Brown	Medical Oncologist, committee member
Victoria Carter	Implementation Support Manager, NICE
Ana Semedo	Vice Chair, Oncology Cancer Nurse
Rose Woodward	Lay member, committee member

1. Welcome, Introductions and DOIs

The Chair, Baljit Singh (BS) welcomed the committee members and NICE attendees to day 1 of the 11th committee meeting for the NICE Kidney Cancer guideline.

BS informed attendees that apologies had been received as noted above. BS asked all committee members to verbally declare any new interests.

No new interests were declared but BS reminded the group of the following recorded interest which are relevant to the day's discussion:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Tze Min Wah	Professor of Interventional Radiology & Consultant Diagnostic and Interventional Radiologist, Leeds Teaching Hospitals NHS Trust	Chan VW, Lenton J, Smith J, Jagdev S, Ralph C, Vasudev N, Bhattarai S, Lewington A, Kimuli M, Cartledge J, Wah TM. Multimodal image-guided ablation on management of renal cancer in Von-Hippel-Lindau syndrome patients from 2004 to 2021 at a specialist centre: A longitudinal observational study. Eur J Surg Oncol. 2022 Mar;48(3):672-679. doi: 10.1016/j.ejso.2021.10.022. Epub 2021 Oct 28. PMID: 34728141.	Specific Direct non-financial professional and personal	Declare and partial exclusion. Participate in discussion but withdraw from drafting recommendations.
Tze Min	Professor of	Osman FH, Chan VW, Breen DJ,	Specific	Declare and partial

Wah	Interventional Radiology & Consultant Diagnostic and Interventional Radiologist, Leeds Teaching Hospitals NHS Trust	King A, Nielsen TK, Garnon J, Alcorn D, Lagerveld B, Graumann O, Keeley FX Jr, Walkden M, de Kerviler É, Wah TM. Oncological and Peri-Operative Outcomes of Percutaneous Cryoablation of Renal Cell Carcinoma for Patients with Hereditary RCC Diseases-An Analysis of European Multi-Centre Prospective EuRECA Registry. Cancers (Basel). 2023 Jun 24;15(13):3322. doi: 10.3390/cancers15133322. PMID: 37444432; PMCID: PMC10340367	Direct non-financial professional and personal	exclusion. Participate in discussion but withdraw from drafting recommendations.
-----	---	--	--	---

Tze Min Wah (TMW) was an author on papers included in the evidence review being discussed. It was agreed that the member could stay for the discussion of the evidence for review question 5c(ii), and to answer any questions but would need to step out whilst recommendations were being made.

Finally, the minutes from committee 10 (day 2) were checked and agreed to be an accurate record.

2. RQ5c(i) (Which adults with renal cell carcinoma should be offered genetic assessment?)

- **Committee discussion**
- **Recommendation drafting**

The Chair introduced Marie Harrisingh (MH), Topic Lead who led a discussion about genetic assessment for adults with renal cell carcinoma. No evidence was presented.

Taking input from the committee to draft the initial wording, the NICE team were able to draft recommendations for genetic assessment that would be taken away for further edits.

BS thanked MH for her contribution.

3. RQ5c(ii) (What is the clinical and cost effectiveness of different interventions (surgical or non-surgical) or active surveillance, compared to each other and different follow up strategies compared to each other for adults with heritable renal cell carcinoma?)

- **Presentation of clinical evidence**
- **Presentation of health economic evidence**
- **Health and health inequality issues**

<ul style="list-style-type: none"> • Committee discussion
<p>The Chair introduced Sarah Matthews (SM), Technical analyst who presented the clinical evidence, and Hannah Tebbs (HT), Senior Health economist presented the cost-effectiveness evidence for different treatment, active surveillance and follow-up strategies for adults with heritable renal cell carcinoma.</p> <p>The evidence covered people with Von-Hippel-Lindau, Birt-Hogg-Dube syndrome, hereditary leiomyomatosis and renal cell cancer and those with mixed heritable renal cell carcinoma syndromes.</p> <p>The committee had the opportunity to ask questions and discuss the evidence including its relevance and limitations. Any equality issues specific to these populations were noted.</p> <p>BS thanked SM and HT for their presentation.</p>
<p>4. Recommendation Drafting</p>
<p>TMW left the meeting at this point due to a conflict of interest.</p> <p>Taking input from the committee to draft the initial wording, the NICE team were able to draft recommendations for modified treatment and follow-up for heritable renal cell carcinoma predisposition syndromes that would be taken away for further edits.</p> <p>BS thanked the committee for their input.</p>
<p>5. RQ1 (What information do adults with suspected or confirmed RCC want before, during and after treatment, when do they want it, and from which healthcare provider would they want to receive it?)</p> <ul style="list-style-type: none"> • How the question has changed and why • Presentation of evidence • Health and health inequality issues • Committee discussion
<p>The Chair introduced Agnesa Mehmeti (AM), Technical Analyst who presented the qualitative evidence for what information adults with suspected or confirmed renal carcinoma want and how it should be received.</p> <p>The committee had the opportunity to ask questions and discuss the evidence including the themes identified in the review and any health equality and health inequality considerations.</p> <p>Drafting recommendations in this area was deferred to a later meeting.</p> <p>BS thanked AM for her presentation and the committee for their input.</p>
<p>6. Next steps and AOB</p>

Kidney Cancer GCOM 11 (day 1) minutes

BS summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, BS brought the meeting to a close.

Date of next meeting: 08/05/2025

Location of next meeting: Virtual